Ovarian Cancer Research Alliance Teams Up with The Clearity Foundation
In a significant step to bolster support for those affected by ovarian cancer, the Ovarian Cancer Research Alliance (OCRA) is merging with The Clearity Foundation. This partnership represents an important advancement in patient advocacy and support, with the goal of establishing a stronger framework for individuals facing ovarian cancer challenges.
What This Merger Means
Effective January 1, 2025, this merger will unite two esteemed organizations dedicated to improving ovarian cancer care. OCRA has been a frontrunner in research, advocacy, and patient support, while Clearity has become well-known for its commitment to scientific education and personalized aid tailored for women and families navigating ovarian cancer diagnoses.
The Vision Behind the Collaboration
The coming together of these two organizations is expected to broaden and deepen the services available to patients and their caregivers. By combining their expertise, they aim to create a cohesive support system that not only addresses patients' immediate needs but also informs them about advanced treatment options and the latest research in ovarian cancer.
Words from the Leaders
Audra Moran, OCRA's President and CEO, shared her excitement regarding the merger: "OCRA has greatly admired the exceptional work Clearity has done for the ovarian cancer community. We are thrilled to welcome Clearity into the OCRA family. Integrating Clearity’s vital programs under our umbrella allows us to build a stronger, more comprehensive education and support system for all those affected by ovarian and gynecologic cancers." This commitment signals a fresh era of collaboration aimed at amplifying patient voices and ensuring their needs are met.
Clearity's Trusted History
Since its founding in 2008, Clearity has been a reliable resource for the ovarian cancer community, providing science-based education, personalized counseling, and tailored resources for clinical trials. Their mission aligns closely with OCRA's, both striving to improve survival rates and quality of life for women diagnosed with ovarian cancer. This merger is poised to harness OCRA’s extensive resources alongside Clearity’s specialized expertise, ultimately enhancing the support offered to patients and their families.
Future Prospects for OCRA and Clearity
The integration of Clearity will aim to create a more comprehensive resource platform that meets the varied needs of those affected by ovarian cancer. Hillary Theakston, Executive Director of Clearity Foundation, emphasized, "Joining forces with OCRA will help fulfill Clearity's aspiration to support the thousands who require personalized emotional and scientific aid tailored to their distinct needs." This partnership seeks to empower patients and their families to confidently navigate their cancer journey, guided by cutting-edge scientific insights.
Active Leadership
As part of this merger, Laura Shawver, Ph.D., founder of Clearity and an ovarian cancer survivor, will join the Board of Directors at OCRA. Her unique insights and experiences will be invaluable in shaping the direction of their combined efforts. The organizations plan to share more specific details about their integrated programs and services in the months ahead, all centered on one common goal: improving support for the ovarian cancer community.
About the Ovarian Cancer Research Alliance
Founded in 1994 and committed to the fight against ovarian cancer, OCRA has invested more than $128 million into scientific breakthroughs and secured $3.8 billion in federal research funding. Their extensive programs and advocacy support around 95,000 individuals annually, significantly impacting the lives of ovarian cancer patients and their loved ones.
Frequently Asked Questions
What is the purpose of the OCRA and Clearity Foundation merger?
The merger is designed to unify resources and efforts, leading to improved support and educational resources for the ovarian cancer community.
When will the merger between OCRA and Clearity Foundation take effect?
The merger is slated to take effect on January 1, 2025.
How has Clearity contributed to the ovarian cancer community?
Since 2008, Clearity has offered science-based education, one-on-one counseling, and clinical trial resources to assist ovarian cancer patients.
What benefits can ovarian cancer patients expect from this merger?
This merger is expected to create a more robust support system for patients, providing comprehensive resources, customized education, and emotional support.
Who will lead the organizations after the merger?
Laura Shawver, Ph.D., founder of Clearity and an ovarian cancer survivor, will join the OCRA Board of Directors, helping to guide the organizations’ combined efforts.
